This Program Project Grant application focuses on hemopoietic stem cell gene therapy with emphasis on stem cell gene therapy for the beta-chain hemoglobinopathies. The program addresses two aspects of Gene Therapy: globin gene therapy of patients with severe beta-thalassemia (thalassemia major or Cooley's anemia) using currently available lentiviral vector technologies;and the development of tools and approaches that will have an impact on gene therapy of the future. The program consists of four Projects and three Core Units. The objective of Project 1 is to identify all the potential chromatin insulators of the human genome, validate their insulator function, and develop new potent chromatin insulators for use in gene therapy vectors. The goal of Project 2 is to advance gene therapy of thalassemia by the approach of gene correction using iPS cells produced from mesenchymal cells or CD34 cells of patients with betathalassemia major. Project 3 addresses the question of bone marrow conditioning that is required for engraftment of corrected stem cells and proposes studies in animal models (mice and primates) that will result in the development of novel, less toxic bone marrow conditioning. Project 4 proposes a stem cell gene therapy clinical trial in patients with beta-thalassemia major. The trial will take place in two sites (New York and Thessaloniki, Greece) and will address the questions of safety and efficacy of stem cell mobilization and of bone marrow conditioning regimens in addition to the question of safety and efficacy of lentiviral globin gene transfer. Three core units support the projects. Core Unit A is the Administrative/ Clinical Regulatory core unit. Core Unit B is the Gene Therapy unit which will assist in the implementation of the clinical trial Core Unit C is the Genomics unit which will provide high throughput genomic services including vector integration site analysis for the patients to be treated with the lentiviral globin vectors. It is expected that the combined talent and expertise of the investigators of the basic sciences projects will lead to breakthroughs that will have an impact on the development of future gene therapy. It is also expected that the proposed clinical trials will answer the question of safety and efficacy of globin gene therapy in patients with betathalassemia major. Beta thalassemia and sickle cell disease are. among the most common genetic diseases in the world affecting several hundred thousand individuals. Although palliative treatments are available the only curative therapy is transplantation of bone marrow, but this therapy is available only to the minority of patients who have a compatible bone marrow donor. The focus of this Program Project, Gene Therapy, can provide a new paradigm for the treatment of these hemoglobinopathies as well as for other blood diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL053750-18
Application #
8282781
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Qasba, Pankaj
Project Start
1996-09-01
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
18
Fiscal Year
2012
Total Cost
$2,383,844
Indirect Cost
$767,120
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Constantinou, Varnavas C; Bouinta, Asimina; Karponi, Garyfalia et al. (2017) Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with ?-thalassemia major. Transfusion 57:1031-1039
Gori, Jennifer L; Butler, Jason M; Kunar, Balvir et al. (2017) Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates. Stem Cells Transl Med 6:864-876
Psatha, Nikoletta; Karponi, Garyfalia; Yannaki, Evangelia (2016) Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-39
Li, Li B; Ma, Chao; Awong, Geneve et al. (2016) Silent IL2RG Gene Editing in Human Pluripotent Stem Cells. Mol Ther 24:582-91
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner et al. (2015) Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-9
Vierstra, Jeff; Reik, Andreas; Chang, Kai-Hsin et al. (2015) Functional footprinting of regulatory DNA. Nat Methods 12:927-30
Qi, Heyuan; Liu, Mingdong; Emery, David W et al. (2015) Functional validation of a constitutive autonomous silencer element. PLoS One 10:e0124588
Liu, Mingdong; Maurano, Matthew T; Wang, Hao et al. (2015) Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 33:198-203
Polak, Paz; Karli?, Rosa; Koren, Amnon et al. (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360-364
Watts, Korashon L; Beard, Brian C; Wood, Brent L et al. (2014) No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42:497-504

Showing the most recent 10 out of 161 publications